Yohann Bohbot1, Christophe de Meester de Ravenstein2, Gagandeep Chadha1, Dan Rusinaru3, Khadija Belkhir1, Camille Trouillet4, Agnes Pasquet2, Sylvestre Marechaux5, Jean-Louis Vanoverschelde2, Christophe Tribouilloy6. 1. Department of Cardiology, Amiens University Hospital, Amiens, France. 2. Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 3. Department of Cardiology, Amiens University Hospital, Amiens, France; EA 7517 MP3CV Jules Verne University of Picardie, Amiens, France. 4. Division of Clinical Research and Innovation, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France. 5. EA 7517 MP3CV Jules Verne University of Picardie, Amiens, France; Groupement des Hôpitaux de l'Institut Catholique de Lille/Faculté libre de médecine, Université Lille Nord de France, Lille, France. 6. Department of Cardiology, Amiens University Hospital, Amiens, France; EA 7517 MP3CV Jules Verne University of Picardie, Amiens, France. Electronic address: tribouilloy.christophe@chu-amiens.fr.
Abstract
OBJECTIVES: This study sought to determine the best left ventricular ejection fraction (LVEF) cutoff value to predict long-term mortality in patients with asymptomatic or minimally symptomatic severe aortic stenosis (AS) and LVEF ≥50% under conservative management and after surgical correction of AS. BACKGROUND: Aortic valve replacement (AVR) is a Class I indication in asymptomatic patients with severe AS and LVEF <50%. However, this is an uncommon situation in asymptomatic severe AS (<1% of patients), usually occurring late in the course of the disease. No data are available concerning the prognostic value of LVEF in asymptomatic or minimally symptomatic AS patients with preserved LVEF (≥50%) in order to identify a LVEF threshold value associated with increased mortality. METHODS: This analysis included 1,678 patients with preserved LVEF and no or minimal symptoms, with a diagnosis of severe AS. The population was divided into 3 groups: LVEF <55%, LVEF 55% to 59%, and LVEF ≥60%. RESULTS: Five-year survival rate was 72 ± 2% for patients with LVEF ≥60%, 74 ± 2% for patients with LVEF between 55% and 59%, and 59 ± 4% for patients with LVEF <55% (p < 0.001). Under initially conservative or initially surgical management (surgery within 3 months after baseline echocardiography), patients with LVEF <55% displayed significant excess mortality compared to patients with LVEF≥ 60% (adjusted hazard ratio [HR]: 2.44 [95% confidence interval: 1.51 to 3.94]; p < 0.001 and 2.51 [95% confidence interval: 1.58 to 4.00]; p < 0.001, respectively), whereas patients with LVEF between 55% and 59% had comparable prognosis to those with LVEF ≥60% (p = 0.53 and p = 0.36, respectively). In patients with LVEF <55%, initial conservative management was associated with increased mortality compared to initial surgical management, even after covariate adjustment (adjusted hazard ratio [HR]: 2.70 [95% confidence interval: 1.98 to 3.67]; p < 0.001). CONCLUSIONS: In patients with severe AS, preserved LVEF and no or minimal symptoms at the time of diagnosis, LVEF <55% is a marker of poor outcome, with medical or surgical management suggesting that these patients should be considered for surgery before this stage.
OBJECTIVES: This study sought to determine the best left ventricular ejection fraction (LVEF) cutoff value to predict long-term mortality in patients with asymptomatic or minimally symptomatic severe aortic stenosis (AS) and LVEF ≥50% under conservative management and after surgical correction of AS. BACKGROUND: Aortic valve replacement (AVR) is a Class I indication in asymptomatic patients with severe AS and LVEF <50%. However, this is an uncommon situation in asymptomatic severe AS (<1% of patients), usually occurring late in the course of the disease. No data are available concerning the prognostic value of LVEF in asymptomatic or minimally symptomatic AS patients with preserved LVEF (≥50%) in order to identify a LVEF threshold value associated with increased mortality. METHODS: This analysis included 1,678 patients with preserved LVEF and no or minimal symptoms, with a diagnosis of severe AS. The population was divided into 3 groups: LVEF <55%, LVEF 55% to 59%, and LVEF ≥60%. RESULTS: Five-year survival rate was 72 ± 2% for patients with LVEF ≥60%, 74 ± 2% for patients with LVEF between 55% and 59%, and 59 ± 4% for patients with LVEF <55% (p < 0.001). Under initially conservative or initially surgical management (surgery within 3 months after baseline echocardiography), patients with LVEF <55% displayed significant excess mortality compared to patients with LVEF≥ 60% (adjusted hazard ratio [HR]: 2.44 [95% confidence interval: 1.51 to 3.94]; p < 0.001 and 2.51 [95% confidence interval: 1.58 to 4.00]; p < 0.001, respectively), whereas patients with LVEF between 55% and 59% had comparable prognosis to those with LVEF ≥60% (p = 0.53 and p = 0.36, respectively). In patients with LVEF <55%, initial conservative management was associated with increased mortality compared to initial surgical management, even after covariate adjustment (adjusted hazard ratio [HR]: 2.70 [95% confidence interval: 1.98 to 3.67]; p < 0.001). CONCLUSIONS: In patients with severe AS, preserved LVEF and no or minimal symptoms at the time of diagnosis, LVEF <55% is a marker of poor outcome, with medical or surgical management suggesting that these patients should be considered for surgery before this stage.
Authors: Rasmus Carter-Storch; Nils Sofus Borg Mortensen; Nicolaj Lyhne Christensen; Mulham Ali; Kristian Bach Laursen; Patricia A Pellikka; Jacob Eifer Moller; Jordi S Dahl Journal: Open Heart Date: 2021-02
Authors: Belinda Ding; Mark Peterzan; Ferenc E Mózes; Oliver J Rider; Ladislav Valkovič; Christopher T Rodgers Journal: NMR Biomed Date: 2021-04-07 Impact factor: 4.478
Authors: Kimi Owashi; Marion Taconné; Nicolas Courtial; Antoine Simon; Mireille Garreau; Alfredo Hernandez; Erwan Donal; Virginie Le Rolle; Elena Galli Journal: J Cardiovasc Dev Dis Date: 2022-02-06
Authors: Mark A Peterzan; William T Clarke; Craig A Lygate; Hannah A Lake; Justin Y C Lau; Jack J Miller; Errin Johnson; Jennifer J Rayner; Moritz J Hundertmark; Rana Sayeed; Mario Petrou; George Krasopoulos; Vivek Srivastava; Stefan Neubauer; Christopher T Rodgers; Oliver J Rider Journal: Circulation Date: 2020-05-22 Impact factor: 29.690